Structural and dynamic studies of a non-self-complementary dodecamer DNA duplex.

Por Fawthrop, S A, Yang, J C, Fisher, J
Publicado em 1993

The clinical diagnosis of splenomegaly.

Por Yang, J. C., Rickman, L. S., Bosser, S. K.
Publicado em 1991

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Por Rosenberg, S A, Yang, J C, White, D E, Steinberg, S M
Publicado em 1998

Seroprevalence and specificity of human responses to the Plasmodium falciparum rhoptry protein Rhop-3 determined by using a C-terminal recombinant protein.

Por Yang, J C, Blanton, R E, King, C L, Fujioka, H, Aikawa, M, Sam-Yellowe, T Y
Publicado em 1996

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Por Rosenberg, S A, Lotze, M T, Yang, J C, Aebersold, P M, Linehan, W M, Seipp, C A, White, D E
Publicado em 1989

Chemical modification of a variant of human MIP-1alpha; implications for dimer structure.

Por Ashfield, J. T., Meyers, T., Lowne, D., Varley, P. G., Arnold, J. R., Tan, P., Yang, J. C., Czaplewski, L. G., Dudgeon, T., Fisher, J.
Publicado em 2000

A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant.

Por Judah, D J, Hayes, J D, Yang, J C, Lian, L Y, Roberts, G C, Farmer, P B, Lamb, J H, Neal, G E
Publicado em 1993

The development of gene therapy for the treatment of cancer.

Por Rosenberg, S A, Anderson, W F, Blaese, M, Hwu, P, Yannelli, J R, Yang, J C, Topalian, S L, Schwartzentruber, D J, Weber, J S, Ettinghausen, S E
Publicado em 1993

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Por Nguyen, H G, Yang, J C, Kung, H-J, Shi, X-B, Tilki, D, Lara, P N, DeVere White, R W, Gao, A C, Evans, C P
Publicado em 2014

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies

Por Lin, C-C, Su, W-C, Yen, C-J, Hsu, C-H, Su, W-P, Yeh, K-H, Lu, Y-S, Cheng, A-L, Huang, D C-L, Fritsch, H, Voss, F, Taube, T, Yang, J C-H
Publicado em 2014

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor

Por Guo, W, Liu, R, Bhardwaj, G, Yang, J C, Changou, C, Ma, A-H, Mazloom, A, Chintapalli, S, Xiao, K, Xiao, W, Kumaresan, P, Sanchez, E, Yeh, C-T, Evans, C P, Patterson, R, Lam, K S, Kung, H-J
Publicado no Cell Death Dis (2014)

Single-domain multiferroic BiFeO(3) films

Por Kuo, C.-Y., Hu, Z., Yang, J. C., Liao, S.-C., Huang, Y. L., Vasudevan, R. K., Okatan, M. B., Jesse, S., Kalinin, S. V., Li, L., Liu, H. J., Lai, C.-H., Pi, T. W., Agrestini, S., Chen, K., Ohresser, P., Tanaka, A., Tjeng, L. H., Chu, Y. H.
Publicado no Nat Commun (2016)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Por Schuler, M., Yang, J. C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V. K., Planchard, D.
Publicado no Ann Oncol (2016)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Por Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.
Publicado no Ann Oncol (2017)